INSTITUTE FOR CANCER RESEARCH, THE holds $2.7M across 7 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Jul 30, 2026 PoP end — agencies typically plan 12–18 months ahead.
TASK ORDER AWARD "NOVEL NON-COX INHIBITORY SULINDAC DERIVATIVE FOR COLORECTAL CANCER CHEMOPREVENTION WITH SELECTIVE PDE-10 AND WNT/B-CATENIN INHIBITORY ACTIVITY
Current PoP ends Jul 30, 2026 (3 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Track recompete timing in SCOUT →INSTITUTE FOR CANCER RESEARCH, THE — $2.7M obligated across 7 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open INSTITUTE FOR CANCER RESEARCH, THE’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →